ADAR1 Capital Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

ADAR1 Capital Management’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$526K	Sell	27,000 -430,137	-94%	-$7.8M	0.02%	208
2026 Q1	$8.52M	Buy	+457,137	New	+$7.57M	0.5%	48
2025 Q4	–	Sell	-151,495	Closed	-$1.09M	–	286
2025 Q3	$1.09M	Buy	151,495 +117,181	+341%	+$6.11M	0.1%	98
2025 Q2	$1.62M	Buy	34,314 +28,890	+533%	+$1.18M	0.25%	63
2025 Q1	$212K	Sell	5,424 -12,000	-69%	-$517K	0.04%	145
2024 Q4	$944K	Sell	17,424 -6,033	-26%	-$308K	0.19%	82
2024 Q3	$1.18M	Buy	23,457 +18,657	+389%	+$874K	0.19%	62
2024 Q2	$211K	Buy	4,800 +1,800	+60%	+$76.2K	0.04%	140
2024 Q1	$151K	Buy	+3,000	New	+$163K	0.03%	132

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ADAR1 Capital Management's MLTX Position: Q2 2026 in Review

ADAR1 Capital Management reduced its MoonLake Immunotherapeutics (MLTX) stake by 94% in Q2 2026, selling an estimated $7.8M and leaving 27,000 shares worth $526K. The position accounts for 0.02% of the portfolio, ranked #208.

ADAR1 Capital Management first reported a position in MLTX in Q1 2024 and has held it in 9 quarters since. The position peaked at $8.52M in Q1 2026. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

ADAR1 Capital Management held 27,000 shares of MoonLake Immunotherapeutics worth $526K as of Q2 2026.
ADAR1 Capital Management sold 430,137 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $7.8M.
MoonLake Immunotherapeutics made up 0.02% of ADAR1 Capital Management's portfolio in Q2 2026, its #208 holding.
ADAR1 Capital Management first reported a position in MoonLake Immunotherapeutics in Q1 2024 and has held it in 9 quarters since.
ADAR1 Capital Management's MoonLake Immunotherapeutics position peaked at $8.52M in Q1 2026.
173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.